Moreover, in phase I/II randomized double-blind placebo-controlled dose-escalation study (NCT01058343), IFN-K was found to be well-tolerated and significantly reducing the expression of the IFN signature compared to placebo in 28 patients with mild-to-moderate SLE [119]. The gene discussed is IFNA1; the disease is systemic lupus erythematosus.